tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TKPHF Stock Latest News

Takeda granted Priority Review for oveporexton by FDA
The FlyTakeda granted Priority Review for oveporexton by FDA
2d ago
TAK
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
PremiumCompany Announcements
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
2d ago
Takeda raises FY25 core EPS view to 486 yen from 479 yen
PremiumThe Fly
Takeda raises FY25 core EPS view to 486 yen from 479 yen
14d ago
TAK
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
PremiumThe Fly
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
14d ago
TAK
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
PremiumCompany Announcements
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
15d ago
TKPHF Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsTKPHF Upcoming Earnings Report: What to Expect?
16d ago
Takeda announces U.S. availability of Gammagard Liquid ERC
Premium
The Fly
Takeda announces U.S. availability of Gammagard Liquid ERC
21d ago
TAK
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
27d ago
RR
ENB
Takeda resumed with an Overweight at Morgan Stanley
PremiumThe Fly
Takeda resumed with an Overweight at Morgan Stanley
1M ago
TAK
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
PremiumThe Fly
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
1M ago
TAK
HALO
Halozyme announces global collaboration, license agreement with Takeda
PremiumThe Fly
Halozyme announces global collaboration, license agreement with Takeda
1M ago
TAK
HALO
Alumis price target raised to $32 from $18 at Guggenheim
PremiumThe Fly
Alumis price target raised to $32 from $18 at Guggenheim
1M ago
TAK
ALMS
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
PremiumThe FlyTakeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
1M ago
TAK
PTGX
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
Premium
The Fly
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
1M ago
TAK
XOMA
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
Premium
The Fly
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
1M ago
TAK
XOMA
Leerink says Takeda results signal positive readthrough for Alumis
PremiumThe Fly
Leerink says Takeda results signal positive readthrough for Alumis
2M ago
TAK
ALMS
Alumis price target raised to $20 from $14 at H.C. Wainwright
PremiumThe Fly
Alumis price target raised to $20 from $14 at H.C. Wainwright
2M ago
TAK
ALMS
Takeda announces zasocitinib studies met primary, secondary endpoints
PremiumThe Fly
Takeda announces zasocitinib studies met primary, secondary endpoints
2M ago
TAK
Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results
PremiumCompany Announcements
Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results
2M ago
Takeda and Protagonist Showcase Promising Rusfertide Results at ASH 2025
PremiumCompany AnnouncementsTakeda and Protagonist Showcase Promising Rusfertide Results at ASH 2025
2M ago
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
Premium
The Fly
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
2M ago
TAK
PTGX
FDA investigating death following Adzynma treatment
Premium
The Fly
FDA investigating death following Adzynma treatment
3M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >